Venomics to treat refractory esophageal adenocarcinoma
Esophageal adenocarcinoma remains highly refractory, highlighting the urgent need for target-driven strategies beyond conventional cytotoxic therapies.
Convergent transcriptomic evidence identifies ion channel remodeling as a mechanistic hallmark and potential vulnerability in esophageal adenocarcinoma.
Venom-derived peptides, already validated in other clinical indications, provide evolutionarily optimized and highly selective modulators of ion channels.
Target-aligned engineering and rational combination strategies may transform venomics into a precise therapeutic avenue for esophageal adenocarcinoma.
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(26)00064-X
